Francis Chou · Q4 2013
Chou Associates Management
Portfolio at the end of Q4 2013, from the 13F filed February 11, 2014. See the filing on EDGAR ↗
| Company | Weight | Held since | Change |
|---|---|---|---|
| Resolute Forest Products RFP · history | 19.2% | Q2 2013 or earlier | Add 2% |
| Berkshire Hathaway BRK.A · history | 15.2% | Q2 2013 or earlier | No change |
| Nokia NOK · history | 11.5% | Q2 2013 or earlier | Add 900% |
| Sears Holdings SHLD · history | 11.2% | Q2 2013 or earlier | No change |
| Sanofi SNY · history | 6.2% | Q2 2013 or earlier | No change |
| JPMorgan Chase JPM.WS · warrants · history | 6.2% | Q2 2013 or earlier | No change |
| Citigroup C · history | 6.1% | Q2 2013 or earlier | No change |
| Beyond BYON · history | 5.1% | Q2 2013 or earlier | Reduce 16% |
| Wells Fargo WFC.WS · warrants · history | 4.5% | Q2 2013 or earlier | No change |
| Goldman Sachs GS · history | 3.8% | Q2 2013 or earlier | No change |
| MBIA MBI · history | 3.7% | Q2 2013 or earlier | No change |
| Allergan AGN · history | 1.7% | Q2 2013 or earlier | Reduce 54% |
| Bank of America BAC.WS.A · warrants · history | 1.5% | Q2 2013 or earlier | No change |
| BlackBerry BB · history | 1.2% | Q2 2013 or earlier | Add 186% |
| Chunghwa Telecom CHT · history | 1.2% | Q2 2013 or earlier | No change |
| Level 3 Communications LVLT.CV · convertible notes · history | 0.7% | Q2 2013 or earlier | Reduce 95% |
| Ryanair RYAAY · history | 0.2% | Q2 2013 or earlier | No change |
| AstraZeneca AZN · history | 0.2% | Q4 2013 | Buy |
| China Yuchai International CYD · history | 0.2% | Q2 2013 or earlier | No change |
| BP BP · history | 0.1% | Q2 2013 or earlier | No change |
| GSK GSK · history | 0.1% | Q4 2013 | Buy |
| Vodafone VOD · history | 0.1% | Q2 2013 or earlier | No change |
| UTStarcom UTSI · history | 0.1% | Q2 2013 or earlier | No change |
| 23 positions | 100.0% |
Weight is the position's share of the total value in this 13F, not of the whole fund. Price is the value divided by the number of shares, so it's the price at the end of the quarter, as the firm reported it. Change compares share counts with Q3 2013, adjusted for stock splits.
Sector weighting
| Financials & real estate | 40.9% | |
|---|---|---|
| Materials | 19.2% | |
| Consumer discretionary | 16.3% | |
| Technology | 12.8% | |
| Health care | 8.3% | |
| Media & telecom | 2.0% | |
| Industrials | 0.4% | |
| Energy | 0.1% |
What changed from Q3 2013
- Buy AstraZeneca AZN 0.2% of the 13F
- Buy GSK GSK 0.1% of the 13F
- Add 2% Resolute Forest Products RFP 3.0% → 19.2%
- Add 900% Nokia NOK 1.8% → 11.5%
- Add 186% BlackBerry BB 0.1% → 1.2%
- Reduce 16% Beyond BYON 1.1% → 5.1%
- Reduce 54% Allergan AGN 0.6% → 1.7%
- Reduce 95% Level 3 Communications LVLT.CV 12.2% → 0.7%
- Sell MannKind MNKD.CV was 40.0%
- Sell Atlanticus ATLC.CV was 27.5%
- Sell Dell Inc. DELL was 1.9%
- Sell RadioShack RSH was 0.1%
- Sell Primus Telecommunications PTGI was 0.1%
- Sell Sprint S was 0.0%